Geographic Atrophy Market Report 2026

The geographic atrophy market size has grown rapidly in recent years. It will grow from $2.11 billion in 2025 to $2.4 billion in 2026 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to aging population growth, prevalence of age-related macular degeneration, advances in retinal imaging, early ophthalmic drug development, clinical research funding.

The geographic atrophy market size is expected to see rapid growth in the next few years. It will grow to $3.92 billion in 2030 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to approval of novel therapies, expansion of screening programs, integration of ai-based imaging, increased patient awareness, growth of specialty eye care. Major trends in the forecast period include rising development of complement inhibitor therapies, growing focus on early diagnosis of retinal disorders, increased investment in novel ophthalmic drugs, expansion of imaging technologies for disease monitoring, growing clinical trials for amd treatments.

The rising prevalence of age-related macular degeneration (AMD) is expected to drive the growth of the geographic atrophy market in the coming years. AMD is an eye condition that damages the central part of the retina in older adults, making it difficult to see fine details. The aging population is a key factor in the increasing prevalence of AMD, as longer life spans and the natural aging process gradually impair vision, making the eyes more susceptible to the disease. Treatments for geographic atrophy support AMD patients by slowing retinal damage and helping preserve remaining vision. For example, in January 2024, a report by Medical News Today, a US-based digital media company, projected that global AMD cases will increase from 196 million to 288 million by 2040. Consequently, the growing prevalence of AMD is fueling growth in the geographic atrophy market.

Leading companies in the geographic atrophy market are focusing on innovative therapies, such as complement inhibitor therapy, to develop advanced treatment options for geographic atrophy. Complement inhibitor therapy works by slowing an overactive immune response linked to certain diseases, protecting healthy cells from damage, and reducing disease progression. For instance, in February 2025, Astellas Pharma Inc., a Japan-based pharmaceutical company, announced FDA approval of IZERVAY (avacincaptad pegol intravitreal solution) for geographic atrophy. The approval allows IZERVAY to be used without restrictions on dosing duration for treating GA secondary to AMD, providing greater flexibility in disease management and offering longer-term treatment options for patients and healthcare providers.

In January 2025, Bausch + Lomb Corporation, a US-based pharmaceutical and medical device company specializing in eye health products, acquired Whitecap Biosciences LLC for an undisclosed amount. Through this acquisition, Bausch + Lomb aims to expand its portfolio of innovative eye health solutions by incorporating Whitecap Biosciences’ expertise in advanced ocular therapeutics. Whitecap Biosciences LLC is a US-based pharmaceutical company focused on developing novel therapies for ophthalmic diseases, including geographic atrophy.

Major companies operating in the geographic atrophy market are Regeneron Pharmaceuticals Inc, Ocugen Inc, Kodiak Sciences Inc, Apellis Pharmaceuticals Inc, Iveric Bio, Graybug Vision, SparingVision, Alkeus Pharmaceuticals, Kiora Pharmaceuticals, Nanoscope Therapeutics, 4D Molecular Therapeutics, Gensight Biologics, BioMarin Pharmaceutical Inc, Nightstar Therapeutics, MeiraGTx, Retinagenix Inc, Adverum Biotechnologies, AGTC Inc, Editas Therapeutics.

North America was the largest region in the geographic atrophy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the geographic atrophy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the geographic atrophy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the geographic atrophy market by increasing costs of imported ophthalmic drugs, diagnostic imaging equipment, and treatment devices. Eye hospitals and specialty clinics are most affected due to reliance on imported therapies. These tariffs increase treatment costs by raising expenses for advanced imaging and long-term therapeutic management. However, they encourage local drug development, supporting regional innovation in retinal disease treatments.

The geographic atrophy market research report is one of a series of new reports that provides geographic atrophy market statistics, including geographic atrophy industry global market size, regional shares, competitors with a geographic atrophy market share, detailed geographic atrophy market segments, market trends and opportunities, and any further data you may need to thrive in the geographic atrophy industry. This geographic atrophy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Geographic atrophy is an eye disorder that leads to gradual vision loss due to retinal damage. It is a severe form of age-related macular degeneration (AMD) and results in blind spots in central vision.

The main drug categories for geographic atrophy include anti-vascular endothelial growth factor (VEGF) therapy, complement inhibitors, neuroprotective agents, and others. Complement inhibitors are treatments that control an overactive immune response by blocking specific proteins involved in inflammation and cell damage. Diagnostic methods include fundus autofluorescence (FAF), optical coherence tomography angiography (OCT-A), and multifocal electroretinography (mfERG). These treatments are administered via various routes, such as intravitreal, oral, and other methods, and are distributed through multiple channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others.

The geographic atrophy market consists of revenues earned by entities by providing gene therapies, and stem cell therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The geographic atrophy market also includes sales of artificial retinas, and medication. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.